IV Ferric Carboxymaltose (FCM) Reduces Anemia in Late Pregnancy More Effectively Than Oral Iron

Anemia during pregnancy is a widespread health concern, especially in low-income countries like Malawi. A new study published in Nature Medicine shows that a single dose of intravenous ferric carboxymaltose (IV FCM) in the third trimester is far more effective at reducing anemia than traditional oral iron supplements. This finding highlights the potential of IV iron therapy as a game-changer in improving maternal health.

Why Anemia in Pregnancy is a Global Concern

Anemia is a preventable condition that affects millions of pregnant women worldwide, leading to complications such as fatigue, low birth weight, and even maternal death. In Africa, 46% of pregnant women are anemic, making it a pressing public health issue.

Traditional oral iron tablets, while commonly prescribed, often fail to restore adequate hemoglobin levels during the third trimester due to:

  • Limited time before labor.
  • Poor absorption in late pregnancy.
  • Low adherence to treatment due to side effects like nausea and constipation.

The Study at a Glance

Researchers conducted a large trial in Malawi (REVAMP-TT), involving 590 pregnant women between 27–35 weeks of gestation who had hemoglobin levels below 10.0 g/dl.

  • Group 1 (IV FCM): Received a single intravenous infusion of ferric carboxymaltose (20 mg/kg, up to 1,000 mg).
  • Group 2 (Oral Iron): Took 60 mg of elemental iron twice daily for 90 days.

The study followed the women and their infants up to 4 weeks postpartum, focusing on key outcomes like anemia rates at delivery and neonatal birthweight.

Key Findings

  1. Lower Anemia Rates with IV Iron:
    • 46.7% of women in the IV FCM group were anemic at delivery, compared to 67.3% in the oral iron group.
    • This translates to a 26% reduction in anemia with IV FCM.
  2. Safety and Tolerance:
    • No serious side effects or infusion-related reactions were reported.
    • Both groups had similar rates of adverse events.
  3. Birthweight:
    • No significant differences in neonatal birthweight were observed between the two groups.

Why IV FCM is a Game-Changer

  • Faster Results: A single infusion restores iron levels quickly, crucial during the limited time available in late pregnancy.
  • Improved Adherence: Unlike oral iron, which requires daily dosing for months, IV iron is a one-time treatment.
  • Better Tolerance: IV FCM avoids the gastrointestinal side effects often associated with oral iron, making it easier for women to tolerate.

Implications for Global Health

The study suggests that IV ferric carboxymaltose can be safely administered even in basic health centers in remote areas. This could significantly improve maternal health outcomes in resource-limited settings.

What Can Doctors Do?

  1. Advocate for IV Iron Therapy: Educate patients and healthcare providers about the benefits of IV FCM over oral iron for late-pregnancy anemia.
  2. Equip Health Centers: Ensure clinics and hospitals are equipped to safely administer IV FCM.
  3. Support Guidelines: Encourage the integration of IV iron into global antenatal care protocols, especially in high-risk regions.

To register for our next masterclass please click here https://linktr.ee/docpreneur

Melbourne, Australia
(Sat - Thursday)
(10am - 05 pm)